Dendritic cell-based therapeutic cancer vaccines: What we have and what we need

Pawel Kalinski, Julie Urban, Rahul Narang, Erik Berk, Ewa Wieckowski, Ravikumar Muthuswamy

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo-expanded T cells, therapeutic vaccines do not have a direct anti-tumor activity, but aim to reset patients' immune systems to achieve this goal. Recent identification of effective ways of enhancing immunogenicity of tumor-associated antigens, including the use of dendritic cells and other potent vectors of cancer vaccines, provide effective tools to induce high numbers of circulating tumor-specific T cells. However, despite indications that some of the new cancer vaccines may be able to delay tumor recurrence or prolong the survival of cancer patients, their ability to induce cancer regression remains low. Recent reports help to identify and prospectively remove the remaining obstacles towards effective therapeutic vaccination of cancer patients. They indicate that the successful induction of tumor-specific T cells by cancer vaccines is not necessarily associated with the induction of functional cytotoxic T lymphocytes, and that current cancer vaccines may promote undesirable expansion of Treg cells. Furthermore, recent studies also identify the tools to counteract such phenomena, in order to assure the desirable induction of Th1-cytotoxic T lymphocytes, NK-mediated type-1 immunity and appropriate homing of effector cells to tumors.

Original languageEnglish (US)
Pages (from-to)379-390
Number of pages12
JournalFuture Oncology
Volume5
Issue number3
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Cancer Vaccines
Dendritic Cells
Neoplasms
Therapeutics
Cytotoxic T-Lymphocytes
T-Lymphocytes
Immune System
Adoptive Immunotherapy
Passive Immunization
Neoplasm Antigens
Regulatory T-Lymphocytes
Immunity
Vaccination
Vaccines
Recurrence
Drug Therapy
Survival
Antibodies

Keywords

  • Breast cancer
  • Cancer
  • Clinical trials
  • Colorectal cancer
  • CTL
  • Dendritic cells
  • Immunotherapy
  • Melanoma
  • NK cells
  • Ovarian cancer
  • Prostate cancer
  • Signal3
  • Signal4
  • Th1
  • Vaccines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kalinski, P., Urban, J., Narang, R., Berk, E., Wieckowski, E., & Muthuswamy, R. (2009). Dendritic cell-based therapeutic cancer vaccines: What we have and what we need. Future Oncology, 5(3), 379-390. https://doi.org/10.2217/fon.09.6

Dendritic cell-based therapeutic cancer vaccines : What we have and what we need. / Kalinski, Pawel; Urban, Julie; Narang, Rahul; Berk, Erik; Wieckowski, Ewa; Muthuswamy, Ravikumar.

In: Future Oncology, Vol. 5, No. 3, 2009, p. 379-390.

Research output: Contribution to journalArticle

Kalinski, P, Urban, J, Narang, R, Berk, E, Wieckowski, E & Muthuswamy, R 2009, 'Dendritic cell-based therapeutic cancer vaccines: What we have and what we need', Future Oncology, vol. 5, no. 3, pp. 379-390. https://doi.org/10.2217/fon.09.6
Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need. Future Oncology. 2009;5(3):379-390. https://doi.org/10.2217/fon.09.6
Kalinski, Pawel ; Urban, Julie ; Narang, Rahul ; Berk, Erik ; Wieckowski, Ewa ; Muthuswamy, Ravikumar. / Dendritic cell-based therapeutic cancer vaccines : What we have and what we need. In: Future Oncology. 2009 ; Vol. 5, No. 3. pp. 379-390.
@article{15ae6feb9cb74cb68a5757ce20408361,
title = "Dendritic cell-based therapeutic cancer vaccines: What we have and what we need",
abstract = "Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo-expanded T cells, therapeutic vaccines do not have a direct anti-tumor activity, but aim to reset patients' immune systems to achieve this goal. Recent identification of effective ways of enhancing immunogenicity of tumor-associated antigens, including the use of dendritic cells and other potent vectors of cancer vaccines, provide effective tools to induce high numbers of circulating tumor-specific T cells. However, despite indications that some of the new cancer vaccines may be able to delay tumor recurrence or prolong the survival of cancer patients, their ability to induce cancer regression remains low. Recent reports help to identify and prospectively remove the remaining obstacles towards effective therapeutic vaccination of cancer patients. They indicate that the successful induction of tumor-specific T cells by cancer vaccines is not necessarily associated with the induction of functional cytotoxic T lymphocytes, and that current cancer vaccines may promote undesirable expansion of Treg cells. Furthermore, recent studies also identify the tools to counteract such phenomena, in order to assure the desirable induction of Th1-cytotoxic T lymphocytes, NK-mediated type-1 immunity and appropriate homing of effector cells to tumors.",
keywords = "Breast cancer, Cancer, Clinical trials, Colorectal cancer, CTL, Dendritic cells, Immunotherapy, Melanoma, NK cells, Ovarian cancer, Prostate cancer, Signal3, Signal4, Th1, Vaccines",
author = "Pawel Kalinski and Julie Urban and Rahul Narang and Erik Berk and Ewa Wieckowski and Ravikumar Muthuswamy",
year = "2009",
doi = "10.2217/fon.09.6",
language = "English (US)",
volume = "5",
pages = "379--390",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Dendritic cell-based therapeutic cancer vaccines

T2 - What we have and what we need

AU - Kalinski, Pawel

AU - Urban, Julie

AU - Narang, Rahul

AU - Berk, Erik

AU - Wieckowski, Ewa

AU - Muthuswamy, Ravikumar

PY - 2009

Y1 - 2009

N2 - Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo-expanded T cells, therapeutic vaccines do not have a direct anti-tumor activity, but aim to reset patients' immune systems to achieve this goal. Recent identification of effective ways of enhancing immunogenicity of tumor-associated antigens, including the use of dendritic cells and other potent vectors of cancer vaccines, provide effective tools to induce high numbers of circulating tumor-specific T cells. However, despite indications that some of the new cancer vaccines may be able to delay tumor recurrence or prolong the survival of cancer patients, their ability to induce cancer regression remains low. Recent reports help to identify and prospectively remove the remaining obstacles towards effective therapeutic vaccination of cancer patients. They indicate that the successful induction of tumor-specific T cells by cancer vaccines is not necessarily associated with the induction of functional cytotoxic T lymphocytes, and that current cancer vaccines may promote undesirable expansion of Treg cells. Furthermore, recent studies also identify the tools to counteract such phenomena, in order to assure the desirable induction of Th1-cytotoxic T lymphocytes, NK-mediated type-1 immunity and appropriate homing of effector cells to tumors.

AB - Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo-expanded T cells, therapeutic vaccines do not have a direct anti-tumor activity, but aim to reset patients' immune systems to achieve this goal. Recent identification of effective ways of enhancing immunogenicity of tumor-associated antigens, including the use of dendritic cells and other potent vectors of cancer vaccines, provide effective tools to induce high numbers of circulating tumor-specific T cells. However, despite indications that some of the new cancer vaccines may be able to delay tumor recurrence or prolong the survival of cancer patients, their ability to induce cancer regression remains low. Recent reports help to identify and prospectively remove the remaining obstacles towards effective therapeutic vaccination of cancer patients. They indicate that the successful induction of tumor-specific T cells by cancer vaccines is not necessarily associated with the induction of functional cytotoxic T lymphocytes, and that current cancer vaccines may promote undesirable expansion of Treg cells. Furthermore, recent studies also identify the tools to counteract such phenomena, in order to assure the desirable induction of Th1-cytotoxic T lymphocytes, NK-mediated type-1 immunity and appropriate homing of effector cells to tumors.

KW - Breast cancer

KW - Cancer

KW - Clinical trials

KW - Colorectal cancer

KW - CTL

KW - Dendritic cells

KW - Immunotherapy

KW - Melanoma

KW - NK cells

KW - Ovarian cancer

KW - Prostate cancer

KW - Signal3

KW - Signal4

KW - Th1

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=66949138572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949138572&partnerID=8YFLogxK

U2 - 10.2217/fon.09.6

DO - 10.2217/fon.09.6

M3 - Article

C2 - 19374544

AN - SCOPUS:66949138572

VL - 5

SP - 379

EP - 390

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -